Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Video Expert Opinion
Colleague Insights
Living Resources
Conferences
Sign in
Join now
featured
Published in Oncology and
1 other channel

Expert Opinion / Commentary · December 08, 2021

2021 Top Story in Bladder Cancer: Adjuvant Nivolumab vs Placebo in Muscle-Invasive Urothelial Carcinoma

Written by
Guru P. Sonpavde MD

 

 Save  Recommend
 Share

Additional Info

  1. Bajorin DF, Witjes JF, Gschwend JE, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021;384(22):2102-2114.
  2. Bajorin DF. ASCO GU 2021: Adjuvant Nivolumab for Advanced Urothelial Carcinoma Shows Benefits. PracticeUpdate. Accessed November 12, 2021.
  3. Griffiths G, Hall R, Sylvester R, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29(16):2171-2177.
  4. Birtle AJ, Chester JD, Jones RJ, et al. Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). 2020. Clinicaltrials.gov. Accessed November 12, 2021.
  5. 5. Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 2015;16(1):76 - 86.
  6. Rhea LP, Aragon-Ching JB. Advances and Controversies With Checkpoint Inhibitors in Bladder Cancer. Clin Med Insights Oncol. 2021;15:11795549211044963
  7. Bellmunt J, Hussain M, Gschwend JE, et al. IMvigor010 Study Group. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(4):525-537.
  8. Apolo AB. Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer (AMBASSADOR). NCT03244384. Clinicaltrials.gov.
  9. Andresen C. Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations. NCT04197986. Clinicaltrials.gov.
  10. Carret AS, Narayanan S. A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer (EV-103). NCT03288545. Clinicaltrials.gov

Disclosure statements are available on the authors' profiles:

Guru Sonpavde MD

Further Reading

Most Read This Week

Recently Updated